🔬 #CancerResearch Update: Top Trials Experts Are Watching in 2025

 At #AACR2025, we asked oncology leaders which clinical breakthroughs could redefine cancer care. Here’s what’s on their radar:

💡 Key Developments to Watch

1️⃣ CTLA-4 + PD-1 Combos
"Microsatellite-stable colorectal cancer may finally meet its match with CTLA-4 inhibitors," says Catherine Sabatos-Peyton (Larkspur Biosciences). Could combo therapies sensitize resistant tumors?

2️⃣ Mitochondrial Therapies
Niven Narain (BPGbio) highlights trials targeting tumor metabolism and CRISPR’s potential: "If we crack off-target effects, gene editing could be transformative."

3️⃣ Next-Gen Targeted Drugs
Christian Schafmeister (ThirdLaw Molecular) tracks:

• Bispecific T-cell engagers (BiTEs)

• KRAS inhibitors for "undruggable" cancers

• Stapled peptides for precision protein modulation

4️⃣ mRNA Cancer Vaccines
Mads Hald Andersen (IO Biotech) eyes Moderna/Merck’s mRNA-4359 (PD-L1/IDO vaccine) and BioNTech’s iNeST platform: "Will mRNA outperform peptide vaccines?"

5️⃣ CAR-T for Solid Tumors
David Craig (City of Hope) awaits data: "If CAR-T works in solid tumors, it’s a game-changer for outcomes."

🚀 Why This Matters

These trials could unlock:
✅ New combo immunotherapies
✅ Drugging the ‘undruggable’
✅ Vaccines that train immunity

#Oncology #Immunotherapy #PrecisionMedicine #ClinicalTrials

👇 Which innovation excites YOU most?